A venous thrombus most often occurs in the deep veins of the legs or pelvis and is then called a deep vein thrombosis (DVT). The clot may dislodge and travel to the lungs to cause a pulmonary embolism (PE).
A DVT can be very difficult to diagnose but early recognition and appropriate treatment can save many lives. A thrombus either arises spontaneously or is predisposed by such conditions as surgery, trauma or prolonged bed rest. They usually form in the deep veins of the lower limbs but may extend higher and into the pelvic veins. The close relationship between DVT and pulmonary embolism (PE) is such that the term venous thromboembolism (VTE) is often used to cover both conditions.
March 2018 - Dr Hayley Willacy draws your attention to the recently released National Institute for Health and Care Excellence (NICE) Guideline on assessing and reducing the risk of hospital-acquired DVT or PE for adults. It advises that all patients should be assessed to identify the risk of VTE and bleeding. This includes all medical, surgical, pregnant women and women who gave birth or had a miscarriage (or termination of pregnancy) in the preceding six weeks, as well as people admitted to the critical care unit and acute psychiatric patients. People should be assessed as soon as possible after admission to hospital or by the time of the first consultant review. They should be assessed using a tool published by a national UK body, professional network or peer-reviewed journal. You should balance the person's individual risk of VTE against their risk of bleeding when deciding whether to offer pharmacological thromboprophylaxis. If using pharmacological VTE prophylaxis, it should be started as soon as possible and within 14 hours of admission, unless otherwise stated in the population-specific recommendations.
- DVT has an annual incidence of about 1 in 1,000 people.
- Major risk factors for VTE include a prior history of DVT, age over 60 years, surgery, obesity, prolonged travel, acute medical illness, cancer, immobility, thrombophilia and pregnancy.
- One study found that 50-70% of patients had readily identifiable risk factors.
- Many cases of DVT and PE remain undiagnosed, even when they are the immediate cause of death. PE is clinically suspected in less than half the people who die from it. DVT can be found in 70-80% of people with PE if sensitive diagnostic tools are used but signs of DVT are only present in 15%.
Risk factors for VTE
- Previous history of VTE. A previous episode of DVT is the strongest risk factor for DVT with a five-fold increase over baseline risk.
- Family history of VTE.
- Age >60.
- Immobilisation. This may be permanent or a temporary risk. Examples include after a stroke, people in plaster casts following fractures, long-distance travel and postoperative recovery. Major surgery, especially if there was an operation on the abdomen or lower limb, is a common preventable cause.
- BMI over 30 kg/m2.
- Male gender.
- Acquired or familial thrombophilia.
- Heart failure.
- Varicose veins.
- Trauma to the vein or chronic low-grade injury (vasculitis, stasis, chemotherapy).
- The combined oral contraceptive pill and hormone replacement therapy.
- Antiphospholipid syndrome.
The clinical diagnosis of DVT can be very difficult. Many DVTs progress to PE without DVT being clinically apparent. In those with classic clinical signs, only about a third have DVT. Classical features are a result of obstruction to venous drainage:
- Limb pain and tenderness along the line of the deep veins.
- Swelling of the calf or thigh (usually unilateral). Involvement of the iliac bifurcation, the pelvic veins or the vena cava produces leg oedema that is usually bilateral.
- Pitting oedema.
- Distension of superficial veins.
- Increase in skin temperature.
- Skin discoloration (erythema or occasionally purple or cyanosed).
- A palpable cord (hard, thickened palpable vein).
Cellulitis adds to the problem:
- Severe signs of DVT can resemble cellulitis.
- Secondary cellulitis may develop with primary DVT.
- Primary cellulitis may be followed by a secondary DVT.
- Superficial thrombophlebitis may hide an underlying DVT.
Other diagnoses should be considered, including:
- Superficial thrombophlebitis.
- Post-thrombotic syndrome.
- Peripheral oedema, heart failure, cirrhosis, nephrotic syndrome.
- Venous or lymphatic obstruction.
- Arteriovenous fistula and congenital vascular abnormalities.
- Ruptured Baker's cyst.
- Septic arthritis.
- Compartment syndrome.
Assessment and investigations
National Institute for Health and Care Excellence (NICE) recommendations
- If a patient presents with signs or symptoms of DVT, carry out an assessment of general medical history and a physical examination to exclude other causes.
- Offer patients in whom DVT is suspected and with a likely two-level DVT Wells' score (see below) either:
- A proximal leg vein ultrasound scan carried out within four hours of being requested and, if the result is negative, a D-dimer test (see below); or
- A D-dimer test and an interim 24-hour dose of a parenteral anticoagulant (if a proximal leg vein ultrasound scan cannot be carried out within four hours) and a proximal leg vein ultrasound scan carried out within 24 hours of being requested.
- Repeat the proximal leg vein ultrasound scan 6-8 days later for all patients with a positive D-dimer test and a negative proximal leg vein ultrasound scan.
- Offer patients in whom DVT is suspected and with an unlikely two-level DVT Wells' score a D-dimer test and, if the result is positive, offer either:
- A proximal leg vein ultrasound scan carried out within four hours of being requested; or
- An interim 24-hour dose of a parenteral anticoagulant (if a proximal leg vein ultrasound scan cannot be carried out within four hours) and a proximal leg vein ultrasound scan carried out within 24 hours of being requested.
- Diagnose DVT and treat patients with a positive proximal leg vein ultrasound scan.
Consider an alternative diagnosis in patients with:
- An unlikely two-level DVT Wells' score and a negative D-dimer test, or a positive D-dimer test and a negative proximal leg vein ultrasound scan.
- A likely two-level DVT Wells score and a negative proximal leg vein ultrasound scan and a negative D-dimer test, or a repeat negative proximal leg vein ultrasound scan.
Use a scoring system such as the Wells' diagnostic algorithm to assess pre-test probability:
Wells' diagnostic algorithmBecause of the unreliability of clinical features, several diagnostic scoring systems have been validated whereby patients are classified as having a high, intermediate or low probability of developing DVT, based on history and clinical examination.
Score one point for each of the following:
- Active cancer (treatment ongoing or within the previous six months, or palliative).
- Paralysis, paresis or recent plaster immobilisation of the legs.
- Recently bedridden for three days or more, or major surgery within the previous 12 weeks, requiring general or regional anaesthesia.
- Localised tenderness along the distribution of the deep venous system (such as the back of the calf).
- Entire leg is swollen.
- Calf swelling by more than 3 cm compared with the asymptomatic leg (measured 10 cm below the tibial tuberosity).
- Pitting oedema confined to the symptomatic leg.
- Collateral superficial veins (non-varicose).
- Previously documented DVT.
The risk of DVT is likely if the score is two or more, and unlikely if the score is one or less.
- These are specific cross-linked products of fibrin degradation and are raised in patients with VTE. Sensitivity is high but specificity poor.
- High concentrations occur in other disorders, such as malignancy and pregnancy and in other conditions where clots form, as after surgery. The investigation of VTE in pregnancy is fraught with many difficulties.
- Several D-dimer assays are available - eg, ELISA tests or SimpliRED whole blood agglutination test suitable for near patient testing.
Plethysmography involves recording of changes in the size of the limb, due to tissue fluid or pooled blood in the veins. Techniques include photoplethysmography (absorption of light by haemoglobin), strain gauge and electrical impedance (change in calf size or electrical impedance of skin during and after occluding venous outflow).
Imaging is normally carried out by two-dimensional ultrasound but can be by venography, computerised tomography (CT) venography or by magnetic resonance imaging. The choice of definitive test may depend upon local protocols, as none is perfect. All these tests are most sensitive when DVT is symptomatic, when thrombus causes complete venous outflow obstruction and when the clot extends into the upper thigh. False negatives are highest when the thrombus is solely below the knee or above the groin, when obstruction is incomplete and when the patient is asymptomatic.
- Duplex ultrasound is the initial investigation of choice in nearly all patients with suspected DVT:
- Its reliability is dependent upon the skill of the user.
- Major axial veins of the lower limb are well displayed.
- It has a sensitivity of 98.7% and specificity of 100% for above-knee DVT and a sensitivity of 85.2% and specificity of 98.2% for below-knee DVT, when compared with the gold standard (invasive venography).
- Magnetic resonance venography and CT venography may be useful adjuncts, and may be helpful in ascertaining the extent of the DVT.
- Contrast venography has long been 'the gold standard' of diagnosis for DVT but is rarely used in clinical practice now:
- An intravenous (IV) catheter is placed in a dorsal vein of the foot and contrast medium is infused into the vein.
- A tourniquet around the leg occludes the superficial veins and forces contrast into the deep veins.
- A positive result tends to be conclusive but a negative result is less reassuring. It is time-consuming and requires much technical skill to obtain good results.
- It is highly invasive and has substantial morbidity and mortality, unlike the other diagnostic tests for DVT.
- Up to 10% of patients have new thrombosis shortly after a negative venogram. This may be because it missed the original DVT or because IV contrast can trigger thrombosis by causing endothelial injury.
- Extravasation of contrast material into the dorsum of the foot may cause sloughing of tissue.
- Anaphylactoid reactions to contrast material occur in 3% of patients and can cause death.
- Offer all patients diagnosed with unprovoked DVT or PE, who are not already known to have cancer, the following investigations for cancer: a physical examination (guided by the patient's full history), CXR, blood tests (FBC, serum calcium and LFTs) and urinalysis.
- Consider further investigations for cancer, with an abdomino-pelvic CT scan (and a mammogram for women), in all patients aged over 40 years with a first unprovoked DVT or PE who do not have signs or symptoms of cancer based on initial investigation.
- Consider testing for antiphospholipid antibodies in patients who have had unprovoked DVT or PE if it is planned to stop anticoagulation treatment.
- Consider testing for hereditary thrombophilia in patients who have had unprovoked DVT or PE and who have a first-degree relative who has had DVT or PE if it is planned to stop anticoagulation treatment.
Refer people who are likely to have DVT for same-day assessment and management (local protocols may vary).
- Offer a choice of low molecular weight heparin (LMWH) or fondaparinux to patients with confirmed proximal DVT or PE, taking into account comorbidities and contra-indications, with the following exceptions:
- For patients with severe renal impairment or chronic kidney disease Stage 4 or 5 (estimated glomerular filtration rate <30 ml/min/1.73 m2), offer unfractionated heparin (UFH) with dose adjustments based on the activated partial thromboplastin time (aPTT) or LMWH with dose adjustments based on an anti-Xa assay.
- For patients with an increased risk of bleeding, consider UFH.
- Start the LMWH, fondaparinux or UFH as soon as possible and continue it for at least five days (or for those starting warfarin, until the international normalised ratio (INR) is 2 or above for at least 24 hours, whichever is longer.
- Offer LMWH to patients with active cancer and confirmed proximal DVT or PE and continue the LMWH for six months. At six months, assess the risks and benefits of continuing anticoagulation.
- Offer an oral anticoagulant to patients with confirmed proximal DVT or PE within 24 hours of diagnosis and continue for three months. Traditionally, the oral coagulant has been a vitamin K antagonist, usually warfarin. Recently, however, NICE has approved the novel non-anti-vitamin K antagonist anticoagulants (NOACs) - rivaroxaban, dabigatran, and apixaban - for use in the treatment and secondary prevention of DVT and PE[9, 10, 11]. NOACs remain under close scrutiny but many reviews suggest their advantages (most importantly the lack of necessity for monitoring, rapid onset and fewer interactions) outweigh disadvantages (particularly expense and the lack of an immediately acting antidote).
- At three months, assess the risks and benefits of continuing anticoagulant treatment.
- Consider extending the anticoagulant beyond three months for patients with unprovoked proximal DVT if their risk of VTE recurrence is high and there is no additional risk of major bleeding.
- Consider catheter-directed thrombolytic therapy for patients with symptomatic iliofemoral DVT who have symptoms of less than 14 days in duration, good functional status, a life expectancy of one year or more and a low risk of bleeding.
- Provide patients who are having anticoagulation treatment with an 'anticoagulant information booklet' and an 'anticoagulant alert card' and advise them to carry the 'anticoagulant alert card' at all times.
- Do not offer below-knee graduated compression stockings unless to manage symptoms.
- Offer temporary inferior vena caval filters to patients with proximal DVT or PE who cannot have anticoagulation treatment; remove the inferior vena caval filter when the patient becomes eligible for anticoagulation treatment.
- Consider inferior vena caval filters for patients with recurrent proximal DVT or PE despite adequate anticoagulation treatment, only after considering alternative treatments such as increasing target INR to 3-4 for long-term high-intensity oral anticoagulant therapy, or switching treatment to LMWH.
- Thrombolytic therapy directed at the vein, increasingly directly by catheter (catheter-directed thrombolysis, or CDT) has had mixed results in studies. It appears to reduce the risk of post-thrombotic syndrome significantly; however, it is not clear whether it reduces risk of PE or recurrence of DVT.
- When a patient presents with a DVT, try to identify if there is an obvious cause - eg, immobilisation or operation.
- If no cause is apparent and the patient is aged under 40, look for thrombophilia.
- If the patient is aged over 40, think of cancer.
- Many individuals who have a first episode of DVT or PE will have a recurrent event.
- Without anticoagulation, the risk recurrence of VTE (DVT or PE) is thought to be 50% within three months of a PE. Risk of recurrence within the first year of a VTE following three months of anticoagulation is thought to be 8%.
- Risk of recurrence is reduced by the use of compression stockings.
- The most serious complication of DVT is PE. The risk of PE is higher in proximal clots. Thrombosis of the iliofemoral veins carries a worse prognosis with increased incidence of late clinical complications such as post-thrombotic syndrome.
- Post-thrombotic syndrome is a chronic venous hypertension, which may result in pain, swelling, hyperpigmentation, dermatitis, ulcers, gangrene and lipodermatosclerosis.
- It may develop after a DVT, due to damage to the deep veins and their valves.
- It affects 20-40% of patients after DVT of the lower limb and can have a significant impact on quality of life.
- Risks associated with the syndrome include older age, obesity, a history of previous ipsilateral DVT, iliofemoral location of the current thrombosis, failure to recover promptly from the acute symptoms and insufficient quality of oral anticoagulant therapy.
- There is a low risk of post-thrombotic syndrome in patients with asymptomatic DVT.
See separate Prevention of Venous Thromboembolism article.
Further reading and references
Prevention and management of venous thromboembolism; Scottish Intercollegiate Guidelines Network - SIGN (December 2010, updated October 2014)
Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines; European Society for Medical Oncology (2011)
Guideline on aspects of cancer-related venous thrombosis; British Committee for Standards in Haematology (2015)
FSRH Healthcare Statement: Venous Thromboembolism (VTE) and Hormonal Contraception; Faculty of Sexual and Reproductive Healthcare, November 2014
Diagnosis and management of venous thromboembolic diseases; NICE Quality Standard, March 2013
Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing; NICE Clinical Guideline (June 2012, updated Nov 2015)
Deep vein thrombosis; NICE CKS, April 2013 (UK access only)
Ageno W, Agnelli G, Imberti D, et al; Risk factors for venous thromboembolism in the elderly: results of the master registry. Blood Coagul Fibrinolysis. 2008 Oct19(7):663-7.
Pulmonary Embolism; NICE CKS, June 2013 (UK access only)
Previtali E, Bucciarelli P, Passamonti SM, et al; Risk factors for venous and arterial thrombosis. Blood Transfus. 2011 Apr9(2):120-38. doi: 10.2450/2010.0066-10. Epub 2010 Oct 25.
Nijkeuter M, Ginsberg JS, Huisman MV; Diagnosis of deep vein thrombosis and pulmonary embolism in pregnancy: a systematic review. J Thromb Haemost. 2006 Mar4(3):496-500. Epub 2005 Dec 23.
Strijkers RH, Cate-Hoek AJ, Bukkems SF, et al; Management of deep vein thrombosis and prevention of post-thrombotic syndrome. BMJ. 2011 Oct 31343:d5916. doi: 10.1136/bmj.d5916.
Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism; NICE Technology Appraisal Guidance, December 2014
Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism; NICE Technology Appraisal Guidance, June 2015
Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism; NICE Technology Appraisal Guidance, July 2012
Mekaj YH, Mekaj AY, Duci SB, et al; New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag. 2015 Jun 2411:967-77. doi: 10.2147/TCRM.S84210. eCollection 2015.
Watson L, Broderick C, Armon MP; Thrombolysis for acute deep vein thrombosis. Cochrane Database Syst Rev. 2014 Jan 231:CD002783. doi: 10.1002/14651858.CD002783.pub3.
Goldhaber SZ, Bounameaux H; Pulmonary embolism and deep vein thrombosis. Lancet. 2012 May 12379(9828):1835-46. Epub 2012 Apr 10.
Jenkins JS, Michael P; Deep Venous Thrombosis: An Interventionalist's Approach. Ochsner J. 2014 Winter14(4):633-40.
Prandoni P, Kahn SR; Post-thrombotic syndrome: prevalence, prognostication and need for progress. Br J Haematol. 2009 May145(3):286-95. Epub 2009 Feb 13.
Persson LM, Lapidus LJ, Larfars G, et al; Asymptomatic Deep Venous Thrombosis is Associated with a Low Risk of Post-thrombotic Syndrome. Eur J Vasc Endovasc Surg. 2009 May 29.
hey guys I I hope you are all as well as can be. having already asked a question similar to this before I don't want to drag you in this one too much. However recently I feel the side effects of...adame76
Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. Patient Platform Limited has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.